The Codon
Marios GeorgakisA publication about human genetics in drug development, and the future of biotech and medicine
| Platform |  | Pricing | Only free issues | Publishes | Weekly |
|---|---|---|---|---|---|
| Issues | 20 | Founded | 2 years ago | Last Issue | 13 days ago |
| Active | |||||
Read this Newsletter
thecodon.substack.comLatest Issues
Betting on the Lp(a) hypothesis
It has been a sobering few weeks in cardiovascular drug development. On July 31, 2026, Novo Nordisk announced that ziltivekimab, a monoclonal antibody against interleukin-6 (IL-6) failed to reduce major adverse cardiovascular events (MACE)...
Why did IL-6 inhibition fail?
Cardiovascular disease remains the leading cause of death worldwide, largely driven by atherosclerosis. Atherosclerotic plaques grow in medium- and large-sized arteries over decades as a result of the subendothelial accumulation of atheroge...
TYK2 inhibition as an example of genetics-driven drug development
I often write about the role of human genetics in developing therapeutic hypotheses and, therefore, new medicines. Genomic studies link variation in biological pathways to human disease, providing evidence for the involvement of these pathw...
Factor XI inhibition: from human genetic signal to the clinic
Recently, the phase 3 OCEANIC-STROKE trial reported that the activated factor XI inhibitor asundexian reduced recurrent ischemic stroke and major cardiovascular events without increasing intracranial or major bleeding among patients with no...
The cholesterol debate through the lens of human genetics
Lowering low-density lipoprotein cholesterol (LDL-C) has repeatedly proven to successfully reduce cardiovascular risk. Just earlier this year, two clinical trials provided further evidence supporting both more aggressive LDL-C lowering and...
Audience Metrics
Subscribers, engagement, traffic and sponsorship for The Codon.
| Subscribers | Engagement | 71 | Monthly Web Visits | ||
|---|---|---|---|---|---|
| Accepts Sponsors | Estimated Cost per Ad | ||||
Explore More
Authors
The writers behind this newsletter.
Physician-scientist leading a lab at LMU Munich. Writing about human genetics, drug development, and the future of biotech and medicine.
Frequently Asked Questions
How can I access the email archive for The Codon?
You can find recent issues that have been published by The Codon on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
How many subscribers does The Codon have?
To see how many people subscribe to The Codon, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
How can I advertise in The Codon?
Newsletter advertising can be extremely effective when it's done right. Before you pitch The Codon as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
How much does it cost to sponsor a publication like The Codon?
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact The Codon using the contact information provided and ask for a copy of their media kit.
How can I find newsletters related to The Codon?
Scroll up to where it says Related Newsletters to see other publications like The Codon. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
How do I contact The Codon?
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.